

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

January 29, 2024

To,

Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers,
Dalal Street, Mumbai-400001
Script Id: 506365

Subject: Outcome of Board Meeting held on Monday, January 29, 2024

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. January 29, 2024, approved the Un-audited Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2023 along with the Limited Review Report thereon.

1. We are enclosing herewith, a copy of the Un-audited Financial Results for the Quarter and Nine Months Ended December 31, 2023 along with the Limited Review Report thereon by auditor for the Quarter and Nine Months Ended December 31, 2023.
2. Approved the Appointment of M/s Kavita Khatri & Associates Company Secretary as the Secretarial Auditor of the Company for the Financial Year 2023-24.

The Meeting commenced at 04.00 p.m. and concluded at 04.50 p.m.

Thanking you,

Yours faithfully,

For **CHEMO PHARMA LABORATORIES LIMITED**



ASHOK SOMANI
DIRECTOR
(DIN -03063364)



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2023

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Nine Months Ended		Year Ended
		31st Dec., 2023	30th Sept 2023	31st Dec., 2022	31st Dec., 2023	31st Dec., 2022	31st March 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	7,023	4,599	1,868	15,915	3,940	2,951
III	Total Revenue (I + II)	7,023	4,599	1,868	15,915	3,940	2,951
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	54	54	35	131	791	791
	(5) Depreciation and Amortisation Expenses	21	21	33	62	99	131
	(6) Administrative and Other Expenses	183	130	181	801	1,097	1,297
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	258	205	249	994	1,987	2,219
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	6,765	4,394	1,619	14,922	1,953	732
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	6,765	4,394	1,619	14,922	1,953	732
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	6,765	4,394	1,619	14,922	1,953	732
X	Tax Expenses						
	(1) Current Tax	4	-	-	4	-	114
	(2) Tax Adjustment Previous Year	-	-	-	-	-	(18)
	(3) Deferred Tax	-	-	-	-	-	(1,045)
	(4) MAT Credit Entitlement	-	-	-	-	-	1,207
XI	Profit/(Loss) for the period from continuing operations (IX - X)	6,761	4,394	1,619	14,918	1,953	473
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	6,761	4,394	1,619	14,918	1,953	473
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	6,761	4,394	1,619	14,918	1,953	473
XVIII	Earnings per Share :						
	(1) Basic	4.51	2.93	1.08	9.95	1.30	0.32
	(2) Diluted	-	-	-	-	-	-

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Nine Months Ended 31.12.2023 have been reviewed by the Audit Committee in their Meeting held on 29.01.2024 and approved by the Board of Directors of its Meeting held on 29.01.2024. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.



For Chemo Pharma Laboratories Limited

Ashok Somani
Ashok Somani

Director
DIN : 03063364

Date : 29th January, 2024
Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kunud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Char, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001.

• Tel. No. (022)22078382 • CIN No.: L99999MH1942PLC003556

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2023

(Rupees in Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED NINE MONTHS ENDED		AUDITED YEAR ENDED
	31.12.2023	30.09.23	31.12.2022	31.12.2023	31.12.2022	31.03.2023
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	1,304	1,372	844	3,660	1,336	636
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	5,457	3,022	775	11,258	617	(1,045)
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	1,207
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	6,761	4,394	1,619	14,918	1,953	473

For Chemo Pharma Laboratories Limited



A handwritten signature in blue ink, appearing to read 'Ashok Somani'.

Ashok Somani
Director

Date: 29th January, 2024

Place: Mumbai

Sanjay Rane & Associates LLP

CHARTERED ACCOUNTANTS

Phone : +91 (22) 4919 8585
Email : admin@ssrane.net
Website : www.ssraneandco.com
LLP IN : ABZ-0863

LIMITED REVIEW REPORT

To,
Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of CHEMO PHARMA LABORATORIES LIMITED for the quarter ended December 31, 2023 and year to date results for the Nine months period from April 1, 2023 to December 31, 2023 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates LLP
Chartered Accountants
Firm Reg. No. 121089W / W100878


CA. Abhijeet Deshmukh
Partner
Membership No. 129145



Date: January 16, 2024
Place: Mumbai

UDIN: 24129145BKAJNN6971

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are as under;

Re-Appointment of Kavita Khatri & Associates, Practicing Company Secretary as Secretarial Auditors of the Company

Sr. No.	Particulars	Details of Information
1.	Reason for change	Appointment of Secretarial Auditor of the Company as per the provisions of Section 204 of the Companies Act, 2013 read with Companies Rules, 2014
2.	Date of Re-Appointment & terms of appointment	January 29, 2024 For the Financial Year 2023-24
3.	Brief profile	<p>M/s. Kavita Khatri & Associates, is practicing CS firm is currently situated at Mumbai which provide consultancy services in the field of Company Law, Securities Laws and Legal.</p> <p>Ms. Kavita Khatri, Proprietor of the Firm is a qualified Company Secretary from the Institute of Company Secretaries of India having Mem. No. A25076. She has over 13 years of experience of working on diversified assignment in the field of Company Secretarial and Legal. She has also completed LLB from L A Shah Law Collage in Year, 2013 from Gujarat University. Ms. Kavita has also registered in Data Bank of Independent Director and currently holding Position of Woman Independent Director in M/s. Phonewale Limited.</p> <p>Observed as a Member of the Internal Complaint Committee for Sexual Harassment of Women at Workplace at the Office of Official Liquidator from Year 2018 and have Served Ahmedabad Chapter of WIRC of ICSI as Member of as Managing Committee and Various Sub-Committees and Exams of Ahmedabad Chapter over the Years At present, Ms. Kavita Khatri is serving as a Treasure of the Ahmedabad Chapter of WIRC of ICSI.</p>

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN -03063364)

